Retatrutide: A Potential Breakthrough in Weight Loss In Kenosha WI

Retatrutide, an experimental injectable medicationfor type 2 diabetes and obesity, is administered weekly, similar to Ozempic® (Semaglutide) Wegovy®(Semaglutide) and Monjaro (Tirzepatide). Its triple mechanism of action — a gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptor agonist — may make it more effective than other medications like Tirzpatide, which only has two mechanisms and ozempic, that has one mechanism of action. Learn more about how Retatrutide works at our wellness clinic in Kenosha WI below.

---

How Retatrutide Works in Kenosha WI

Retatrutide's "triple attack" on hunger functions by:

1. Slowing stomach emptying after eating, promoting a feeling of fullness
2. Stabilizing post-meal blood sugar spikes, stimulating insulin release, and storing more sugar as glucose
3. Impacting glucagon hormone levels to suppress appetite and increase energy expenditure

---

Promising Weight Loss Results

While still in clinical trials, retatrutide has shown promising results. Participants with obesity who received the highest dose lost an average of 17.5% of their initial weight by the study's midpoint (nearly six months) and over 24% (around 58 lbs) by week 48 (one year). This weight loss is notably greater than that observed with Wegovy® or Ozempic®.

Nearly all 338 adult participants who took lower doses also experienced significant weight reduction, ranging from 5% to 15%. This level of weight loss can lead to improvements in various health markers, including blood pressure, cholesterol levels, and blood sugar control.

---

Potential Side Effects and Risks

The most commonly reported side effects in retatrutide clinical trials were gastrointestinal (GI) issues, similar to those seen with other GLP-1 receptor agonists. These may include nausea, bloating, gas, vomiting, and heartburn. However, it remains unclear whether retatrutide will cause the same GI side effects or other more serious health complications. Further clinical safety trials are needed to fully assess the potential risks associated with retatrutide. Counseling and regular visits are strongly recommended while taking this medication to help monitor diet, symptoms, weight loss, dosing, muscle mass and visceral fat loss.

Weighless MD recommends bi-weekly counseling sessions at the beginning and then eventually transitioning to monthly visits once a stable dose has been reached.

If patients lose a lot of weight and do not know what they are losing, they risk further damaging their metabolic health. Maintaining Muscle mass during weight loss is crucial and targeting visceral effect is just as important as it is the driver of inflammation throughout the body.

Weighlesss MD will be conducting their own study on Retatrutide starting January 13, 2025. The study will consist of 3 phases and they are currently accepting participants to join their waitlist. If you are interested, please provide your information below.

---

Join Our Study